Sanofi-Aventis acquires Genzyme for $74 a share plus contingent $14 per share
This article was originally published in Scrip
Executive Summary
Six months after showing its hand, Sanofi-Aventis has agreed to acquire Genzyme for $74 a share up front plus the promise of additional payments – up to an extra $14 a share – should certain commercial and manufacturing milestones be passed. The $74 a share -- $5 a share higher than the initial offer – values Genzyme at $20.1 billion. In addition to the cash payment, each Genzyme shareholder will receive one contingent value right (CVR) for each share they own, entitling them to additional cash payments should specified milestones be met.
You may also be interested in...
Sanofi Earnings Emphasize Need For Medivation Buy
Sanofi clearly would benefit from its proposed $9.3bn purchase of Medivation Inc. based on the French company's first quarter earnings, which show a pharmaceuticals business that's suffering from competition, US drug pricing pressures and foreign currency exchange issues.
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.